GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients
Conditions
Keywords
bone mineral loss, prostate cancer, GnRH agonist alone vs. GnRH agonist plus anti-androgen combination
Brief summary
Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent
Detailed description
MC MD
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Korean prostate cancer over 50 years old with pathological confirmation * Patients receiving GnRH antagonist or GnRH agonist plus anti- androgen combination within 6 months since starting. * Patients measured bone density level before starting to receive hormone therapies above.
Exclusion criteria
* Patients who are treated other anti-osteoporosis drugs and who are treated bisphosphate due to BMD T score below -3.0. * Patients who are hard to be analysed by attach to other bone disease. * Patients who are hard to be analysed by limitation of chart record according to investigators'discretion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| comparison of bone density before and after hormone therapy | 1 year |
| comparison of bone density between GnRH agonist alone vs. CAB group | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| correlation between osteoporosis risk factors such as age, weight, history of smoke, history of alcohol and bone density value | 1 year |
| correlation between osteoporosis risk factors such as age, weight, history of smoke, history of alcohol and bone density value before and after hormone therapy | 1 year |
| 1year comparison of FRAX score before and after hormonal therapy | 1 year |
Countries
South Korea
Outcome results
None listed